CN108355048A - A kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription - Google Patents
A kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription Download PDFInfo
- Publication number
- CN108355048A CN108355048A CN201810328425.3A CN201810328425A CN108355048A CN 108355048 A CN108355048 A CN 108355048A CN 201810328425 A CN201810328425 A CN 201810328425A CN 108355048 A CN108355048 A CN 108355048A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- radix
- copd
- stable phase
- smoking cessation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to field of traditional Chinese medicine technology, it discloses a kind of aiding smoking cessation and COPD in stable phase Chinese medicine compound prescription can be treated, the Chinese medicine compound prescription is made of cordate houttuynia 30g, wine earthworm 15g, RADIX POLYGALAE PREPARATA 10g, peppermint 6g, campanulaceae 6g, Radix Glycyrrhizae 6g, Radix Codonopsis 10g, Radix Astragali 15g, Radix Ophiopogonis 10g, Radix Salviae Miltiorrhizae 12g and HERBA EPIMEDII 12g.Take suitable weight proportion, full side integrates qi and activate blood circulation, Tongluo Jiedu, prescription has much intention, it is clinically used for the various syndromes that treatment tobacco dependence merges COPD in stable phase, symptoms include dry, insomnia, anxiety, cough, expectoration, shortness of breath are out of breath, pale tongue with thin fur deep thready pulse etc. is smoked COPD patient.
Description
Technical field
The invention belongs to field of traditional Chinese medicine technology, and in particular to a kind of aiding smoking cessation and treatment stationary phase chronic obstructive
Lung disease Chinese medicine compound prescription and its preparation method and application.
Background technology
Chronic Obstructive Pulmonary Disease (COPD) is respiratory system common disease, frequently-occurring disease, average in China 40 years old or more crowd
Illness rate is 8.2%, and the state of an illness constantly progress can finally cause respiratory failure and cor pulmonale, be that the elderly is caused to cause
One of the main reason for residual and dead.The whole world occupies world's cause of death the 4th because of COPD death tolls about 3,000,000 at present, until
The year two thousand twenty, COPD will become the big cause of death in third place in the world.One of main high risk factor of COPD is smoking, the existing cigarette in China
The people 3.16 hundred million, smoking rate 27.7%, and China causes death toll to be more than 1,000,000 because of smoking.COPD Chinese medicine category the lung-distension scopes are more
By lung pattern disease recurrent exerbation, protracted course of disease causes lung, spleen, kidney three dirty deficient caused.The normal recurrent exerbation of this disease, the course of disease is longer,
Simulataneous insufficiency and excessive, because of the difference of human quality, can clinically show different card types, but send out in the different phase of morbidity
Sick key link all has " deficiency of vital energy " and " phlegm-blood stasis ".Stable COPD treatment at present mainly using bronchodilator and/or
The sucking preparation of hormone, but total effective rate is not satisfactory, drug price is high, and exists and pneumonia and cardiovascular event occurs
Risk.The method of smoking cessation mainly has psychology and behavior intervention, medicinal treatment, acupuncture and moxibustion treatment etc., and stop smoking medicine is seldom, and price is high
Expensive, total effective rate is unsatisfactory, and other smoking cessation modes often need use in conjunction, compliance to reduce, and relapse rate increases.Meanwhile
Because long-term smoking causes COPD that more not good unified medicine or method occurs, treatment of smoking cessation ignores controlling for COPD often
It treats, especially early stage COPD patient, impairment of pulmonary function caused by smoking is caused not protect well.And it is Symptomatic treating
When middle patients of severe COPD, treatment of smoking cessation is not carried out well again, causes smoking cessation difficult, the state of an illness is made to be further aggravated.
In conclusion problem of the existing technology is：Carry out aiding smoking cessation currently without good stop smoking medicine, while again
The COPD of caused by smoking can be treated, slow down lung function and further decline.
Invention content
In view of the problems of the existing technology, the purpose of the present invention is to provide a kind of aiding smoking cessation and treatment stationary phase it is slow
Property obstructive disease of lung Chinese medicine compound prescription and its application in COPD patient of smoking.
The invention is realized in this way a kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription,
The aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription (raw meat dragon protects lung side) are by cordate houttuynia 30g, wine
Imperial 15g, RADIX POLYGALAE PREPARATA 10g, peppermint 6g, campanulaceae 6g, Radix Glycyrrhizae 6g, Radix Codonopsis 10g, Radix Astragali 15g, Radix Ophiopogonis 10g, Radix Salviae Miltiorrhizae 12g and HERBA EPIMEDII
12g is formed.
Prescription according to the present invention so that the aiding smoking cessation that available data refers to can treat stationary phase chronic resistance again simultaneously
The Chinese medicine compound prescription theory of plug property lung disease becomes a kind of enforceable technical solution, is applied to the field of Chinese medicines, and shows good
Prevention and treatment effect.
Another object of the present invention is to provide a kind of aiding smoking cessation and treatment COPD in stable phase
The preparation method of Chinese medicine compound prescription (raw meat dragon protect lung side), the aiding smoking cessation and treatment COPD in stable phase Chinese medicine are multiple
Side preparation method include：
(1) prepare each bulk pharmaceutical chemicals by weight ratio；
(2) ready bulk pharmaceutical chemicals are added water to cook, the medicinal extract with active constituents of medicine is condensed into after filtering decoction liquor.
Above-mentioned step (2) is measured water for each 6-10 times and is decocted 0.5-2 hours Preferable scheme is that adding water to cook 1-3 times,
Merge decoction liquor, filter to get filtrate, the medicinal extract that proportion is 1.0-1.3 is condensed into after filtering decoction liquor.
The Chinese medicine compound prescription of the present invention also can be used other conventional methods in existing pharmaceutical field and prepare, can when needs
To add various pharmaceutically acceptable carriers, the pharmaceutically acceptable dosage form of any type can be made into.The carrier includes
Diluent, excipient, adhesive, disintegrant, wetting agent, lubricant, the surfactant etc. of pharmaceutical field routine, such as：Starch,
Sucrose, dextrin, lactose, magnesium stearate, cellulose family and its derivative, gelatin, polyvinylpyrrolidone etc..The Chinese medicine of the present invention
Compound medicine is preferably made oral preparation, such as：Granule, tablet, capsule, ointment, oral solution, soft extract, pill etc..
The present invention compound Chinese medicinal preparation, effective component by cordate houttuynia, wine earthworm, RADIX POLYGALAE PREPARATA, peppermint, campanulaceae, Radix Glycyrrhizae,
Radix Codonopsis, Radix Astragali, Radix Ophiopogonis, Radix Salviae Miltiorrhizae and 11 taste Chinese medicine of HERBA EPIMEDII are made, and take suitable weight proportion, and full side's collection qi and activate blood circulation leads to
Network detoxifies in one, and prescription has much intention, is clinically used for treatment tobacco dependence and merges each of COPD in stable phase
The kind smoking COPD patient such as syndrome symptoms include dry, insomnia, anxiety, cough, expectoration, out of breath, the pale tongue with thin fur deep thready pulse of shortness of breath.
Advantages of the present invention and good effect are：
The present invention compound Chinese medicinal preparation, effective component by cordate houttuynia, wine earthworm, RADIX POLYGALAE PREPARATA, peppermint, campanulaceae, Radix Glycyrrhizae,
Radix Codonopsis, Radix Astragali, Radix Ophiopogonis, Radix Salviae Miltiorrhizae and 11 taste Chinese medicine of HERBA EPIMEDII are made, and take suitable weight proportion, and full side's collection qi and activate blood circulation leads to
Network detoxifies in one, and prescription has much intention, is clinically used for treatment tobacco dependence and merges each of COPD in stable phase
Kind of syndrome symptoms include dry, insomnia, anxiety, cough, expectoration, shortness of breath are out of breath, and pale tongue with thin fur deep thready pulse etc. is smoked COPD patient.
Description of the drawings
Fig. 1 is aiding smoking cessation provided in an embodiment of the present invention and treatment COPD in stable phase Chinese medicine compound prescription
Preparation method flow chart；
Fig. 2 is that DA contains spirogram in each group mouse brain provided in an embodiment of the present invention.
Specific implementation mode
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.
Below in conjunction with the accompanying drawings 1, attached drawing 2 is explained in detail the application principle of the present invention.
Aiding smoking cessation provided in an embodiment of the present invention and treatment COPD in stable phase Chinese medicine compound prescription by fish raw meat
Careless 30g, wine earthworm 15g, RADIX POLYGALAE PREPARATA 10g, peppermint 6g, campanulaceae 6g, Radix Glycyrrhizae 6g, Radix Codonopsis 10g, Radix Astragali 15g, Radix Ophiopogonis 10g, Radix Salviae Miltiorrhizae
12g and HERBA EPIMEDII 12g compositions.
As shown in Figure 1, aiding smoking cessation provided in an embodiment of the present invention and treatment COPD in stable phase Chinese medicine
The preparation method of compound includes the following steps：
S101：Prepare each bulk pharmaceutical chemicals by weight ratio；
S102：Ready bulk pharmaceutical chemicals are added water to cook, the leaching with active constituents of medicine is condensed into after filtering decoction liquor
Cream.
Cordate houttuynia, property and flavor of peppery and cold enter lung channel, have clearing heat and detoxicating and other effects, and it is anti-that modern pharmacology experiment shows that this product has
The effects that bacterium, antiviral, raising immunity of organisms, diuresis.Earthworm, nature and flavor are salty-cold, enter liver and spleen bladder warp, have diuresis, analgesia,
The effects that relievining asthma, be depressured, is antipyretic, is anticonvulsion.Radix Polygalae has antitussive and antiasthmatic, tranquilizing effect；Peppermint head clearing；Campanulaceae profit
Swallow expectoration；Radix Codonopsis and Radix Astragali using tonifying Qi reinforcing lungs, and immunity-regulating；Radix Ophiopogonis supports lung yin, has the benefits of quench one's thirst of promoting the production of body fluid, moisten the lung and relieve the cough；
Radix Salviae Miltiorrhizae is promoting blood circulation and removing blood stasis；HERBA EPIMEDII kidney tonifying dehumidifies；Radix Glycyrrhizae coordinating the drug actions of a prescription.
As shown in Figure 1, the preparation method of compound Chinese medicinal preparation provided in an embodiment of the present invention includes the following steps：
The application principle of the present invention is further described with reference to specific embodiment.
Embodiment 1：The preparation of the active component of drug of the present invention
(1) weigh Chinese medicine material by following weight proportions (by taking 10 times of material proportional quantities as an example)：300 parts of cordate houttuynia, wine
Dragon 150 parts, 100 parts of RADIX POLYGALAE PREPARATA, 60 parts of peppermint, 60 parts of campanulaceae, 60 parts of Radix Glycyrrhizae, 100 parts of Radix Codonopsis, 150 parts of Radix Astragali, 100 parts of Radix Ophiopogonis,
120 parts of 120 parts of Radix Salviae Miltiorrhizae and HERBA EPIMEDII.
(2) cordate houttuynia, wine earthworm, RADIX POLYGALAE PREPARATA, peppermint, campanulaceae, Radix Glycyrrhizae, Radix Codonopsis, Radix Astragali, the wheat of above-mentioned weight proportion are weighed
Winter, Radix Salviae Miltiorrhizae and HERBA EPIMEDII, add water to cook secondary, and 10 times of amount water decoct 2 hours for the first time, and second 8 times of amount water decoct 1 hour,
Decocting liquid filters, and merging filtrate is simultaneously concentrated into relative density as 1.25 (60 DEG C or so), obtains medicinal extract, the as activity of the invention drug
Component.
Embodiment 2：The preparation of tablet
(1) 60 parts of active component being prepared by method in embodiment 1 is taken, adds dextrin 40 part, mixes thoroughly, is dried in vacuo
(40-60 DEG C) is ground into fine powder (sieving with 100 mesh sieve) to after doing.
(2) said medicine fine powder is taken, then is mixed with 60 parts of dextrin and 30 parts of starch, adds 5 part of 10% starch slurry that softwood is made,
It is sieved and is pelletized with 14 mesh, is placed in after 70 DEG C of dryings in 12 mesh sieves, after 0.8 part of magnesium stearate mixing is added, tabletting is to get piece
Agent.
Embodiment 3：The preparation of granule
60 parts of active component being prepared by method in embodiment 1 is taken, 120 parts of sucrose, 80 parts of dextrin, mixing are added.Again
Add 75% ethyl alcohol mixing, softwood be made, sieved and pelletized with 14 mesh, is placed in after 75 DEG C of dryings after 12 mesh sieves, mixing, packs,
Up to granule.
Embodiment 4：The preparation of oral solution
The active component 60ml being prepared by method in embodiment 1 is taken, appropriate PhCOONa solution is added, adds 500ml pure
Change water, filtering.Add purified water to 1000ml to get oral solution.
Embodiment 5：The preparation of capsule
(1) 60 parts of active component being prepared by method in embodiment 1 is taken, adds dextrin 40 part, mixes thoroughly, is dried in vacuo
(40-60 DEG C) is ground into fine powder (sieving with 100 mesh sieve) to after doing.
(2) said medicine fine powder is taken, then is mixed with 60 parts of dextrin and 30 parts of starch, adds 5 part of 10% starch slurry that softwood is made,
It is sieved and is pelletized with 14 mesh, is placed in after 80 DEG C of dryings after 12 mesh sieves, mixing, be packed into snap fit capsule up to capsule.
The experimental study of 1 aiding smoking cessation of test example effect
Active component is made by embodiment 1 in test medicine.
Dose design in vivo studies is converted into mouse according to people's clinical application amount according to animals and human beings kilogram equivalent dose
In vivo studies dosage, it is determined as middle dosage is equivalent to clinical equivalent dosage.As 2 times of middle dosage, low dosage is the another high dose that sets
1/2 times of middle dosage；
Animal KM male mices, 13-15g are raised in barrier environment.
Experimental method：40 KM male mices are randomly divided into 5 groups：Normal group, nicotine dependence model group, drug
Treatment low, middle and high dose groups, every group 8.The daily nicotine 5mg/kg/d of continuous 14 days of mouse be subcutaneously injected structure nicotine according to
Rely model, while giving basic, normal, high dosage raw meat dragon and protecting lung side continuous 2 weeks, it is evaluated using the experiment of spacious case and forced swimming test
Withrawal symptom measures its striatal dopamine levels using high performance liquid chromatography.
Experimental result：The dopamine concentration of middle high dose group is apparently higher than nicotine model group, such as Fig. 2.
Test example 2 treats the clinical research of stationary phase chronic obstructive pulmonary disease
Active component is made by embodiment 1 in test medicine.
Test method：40 COPD stationary phases (D grades) patient is randomly divided into treatment group (20) and control group (20),
Treatment group (is made using people's salmeterol fluticasone powders for inhalation 50/500ug Combined with Oral Chinese medicine compound prescription is inhaled by embodiment 1
Active component), control group inhales people agent 50/500ug using people's salmeterol fluticasone powder is inhaled, and after treating March, evaluates two groups of trouble
Person's clinical symptoms integral, lung function and CAT scorings.
Test result：1. two groups of patient symptom integral contrasts have statistical significance (P=0.002) after treatment；2. treating
(P is equal for every lung function index comparison among groups no difference of science of statistics afterwards>0.05)；3. treatment group patient CAT scorings are better than after treatment
Control group, difference have significant difference (P=0.018).It is shown in Table 1-3.
1 two groups of patient symptom integral contrasts of table
Note：Compared with the control group,*P<0.05.
2 two groups of Pulmonary Functions of table compare
Note：Compared with the control group,*P<0.05.
3 two groups of patient's CAT scorings of table are compared
Note：Compared with the control group,*P<0.05.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
All any modification, equivalent and improvement etc., should all be included in the protection scope of the present invention made by within refreshing and principle.
Claims (4)
1. a kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription, which is characterized in that the aiding smoking cessation
And treatment COPD in stable phase Chinese medicine compound prescription is by mass：Cordate houttuynia 30g, wine earthworm 15g, RADIX POLYGALAE PREPARATA 10g,
Peppermint 6g, campanulaceae 6g, Radix Glycyrrhizae 6g, Radix Codonopsis 10g, Radix Astragali 15g, Radix Ophiopogonis 10g, Radix Salviae Miltiorrhizae 12g, HERBA EPIMEDII 12g.
2. a kind of aiding smoking cessation as described in claim 1 and the preparation side for treating COPD in stable phase Chinese medicine compound prescription
Method, which is characterized in that the aiding smoking cessation and treat COPD in stable phase Chinese medicine compound prescription preparation method include：
Step 1: preparing each bulk pharmaceutical chemicals by weight ratio；
Step 2: ready bulk pharmaceutical chemicals are added water to cook, the medicinal extract with active constituents of medicine is condensed into after filtering decoction liquor.
3. aiding smoking cessation as described in claim 1 and the preparation method for treating COPD in stable phase Chinese medicine compound prescription,
It is characterized in that, in step 2, add water to cook 1-3 times, measures water for each 6-10 times and decoct 0.5-2 hours, merge decoction liquor, mistake
Filtrate is filtered to obtain, the medicinal extract that proportion is 1.0-1.3 is condensed into after filtering decoction liquor.
4. a kind of aiding smoking cessation as described in claim 1 and treatment COPD in stable phase Chinese medicine compound prescription, feature
It is, the instructions of taking of the aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription is：It is oral, daily one
Agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810328425.3A CN108355048A (en) | 2018-04-13 | 2018-04-13 | A kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810328425.3A CN108355048A (en) | 2018-04-13 | 2018-04-13 | A kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108355048A true CN108355048A (en) | 2018-08-03 |
Family
ID=63008312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810328425.3A Pending CN108355048A (en) | 2018-04-13 | 2018-04-13 | A kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108355048A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2185184C1 (en) * | 2001-07-16 | 2002-07-20 | Югов Сергей Дмитриевич | Bronchopulmonary species "fitovit" |
| CN104784464A (en) * | 2015-03-31 | 2015-07-22 | 浙江省中医院 | Traditional Chinese medicine composition and application thereof |
-
2018
- 2018-04-13 CN CN201810328425.3A patent/CN108355048A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2185184C1 (en) * | 2001-07-16 | 2002-07-20 | Югов Сергей Дмитриевич | Bronchopulmonary species "fitovit" |
| CN104784464A (en) * | 2015-03-31 | 2015-07-22 | 浙江省中医院 | Traditional Chinese medicine composition and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 李国光等: "《戒烟限制 健康长寿》", 31 January 2018, 湖北科学技术出版社 * |
| 森惟明: "《最简单的健康自助手边书》", 28 February 2013, 武汉出版社 * |
| 王雪苔: "《中国针灸大全》", 30 June 1992, 湖南科学技术出版社 * |
| 白春学: "《呼吸系统疾病的诊断与鉴别诊断》", 31 May 2004, 天津科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101549060B (en) | Medicament containing gnetales for treating bronchitis and preparation method thereof | |
| CN1320902C (en) | Chinese medicinal composition for clearing heat, dispersing phlegm, ventilating the lung and relieving asthma and process for preparing the same | |
| CN102488849A (en) | Traditional Chinese medicine composition used for treating periodontitis | |
| CN103656410A (en) | Traditional Chinese medicine preparation for treating cough and preparation method thereof | |
| CN102552806B (en) | Fat-burning dredging particles and preparation method thereof | |
| KR20120039688A (en) | A medicine composition for treating bronchial asthma and preparative method thereof | |
| CN103479932B (en) | One treats bronchitic Chinese medicine composition and preparation method thereof | |
| CN105250843A (en) | Medicament for treating cough due to wind-heat evil | |
| CN100408080C (en) | Heart quieting and orifice opening capsule and its preparation | |
| CN108355048A (en) | A kind of aiding smoking cessation and treatment COPD in stable phase Chinese medicine compound prescription | |
| CN102949572A (en) | Medicinal composition for treating throat diseases, and its preparation method | |
| CN102973833B (en) | Pharmaceutical composition for treating bronchitis | |
| CN1181880C (en) | Compound macrostem onion preparation for curing chronic obstructive lung disease and its preparing method | |
| CN1069053C (en) | Oral medicine for curing phlegm-heat cough | |
| CN1403130A (en) | Cough-relieving bagged tea and its prepn | |
| CN106310027A (en) | Compound dendrobium lung-clearing preparation, preparation method and application thereof | |
| CN105125838A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparing method thereof | |
| CN103989762A (en) | Traditional Chinese medicine composition for clearing heat and purging internal organs, and relieving cough and reducing sputum and preparation method thereof | |
| CN101496869B (en) | Chinese medicine preparation for treating bronchitis | |
| CN1830482B (en) | Chinese medicinal composition and application for treating child pneumonia for treating | |
| CN104906337B (en) | A kind of Radix Glycyrrhizae pear Bulbus Fritillariae Ussuriensis and preparation method | |
| CN114917287B (en) | Traditional Chinese medicine composition for treating allergic asthma, preparation method and application thereof | |
| CN110801504B (en) | Traditional Chinese medicine composition for relieving cough and reducing sputum | |
| CN107582834A (en) | A kind of Chinese medicine composition for treating empty asthma | |
| CN101757407B (en) | Traditional Chinese medicine composition for treating asthma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180803 |
|
| RJ01 | Rejection of invention patent application after publication |